Introduction {#s1}
============

An "epigenetic switch is the key to persistent extinction" ([@CIT0021]), a notion supported by experimental evidence suggesting that pharmacological modulation of epigenetic mechanisms such as DNA methylation or histone acetylation can produce lasting suppression of memories (for review, see [@CIT0012]). This seems to be particularly relevant for the psychotherapeutic treatment of anxiety disorders essentially entailing fear extinction ([@CIT0023]).

In female patients with panic disorder, we recently identified hypomethylation of a promoter/exon I/intron I region of the monoamine oxidase A (*MAOA*) gene on chromosome Xp11.4-p11.3 as a disease risk factor ([@CIT0005]), which was found to be reversible with a successful cognitive behavioral psychotherapeutic intervention ([@CIT0025]). The *MAOA* gene is a prime candidate gene also for specific phobias based on evidence from animal studies ([@CIT0009]) and genetic association studies in patients with specific phobias ([@CIT0018]).

Thus, in the present proof-of-concept "psychotherapy-epigenetic" study, we for the first time investigated DNA methylation in the above-mentioned promoter/exon I/intron I region of the *MAOA* gene in female patients with acrophobia during a standardized 2-week cognitive behavioral psychotherapeutic intervention including exposure exercises using virtual reality technology, partly enhanced by repetitive transcranial magnetic stimulation (rTMS). In analogy to a previous study in panic disorder we predicted *MAOA* methylation to increase and thus to "normalize" along with treatment response. Additionally, the functional relevance of altered *MAOA* promoter/exon I/intron I methylation was investigated by means of luciferase-based reporter gene assays.

Methods {#s2}
=======

Sample {#s3}
------

Twenty-eight female Caucasian patients (44.86 ± 13.67 years) with acrophobia (SCID-I) were recruited at the Department of Psychiatry, University of Würzburg, Germany. Exclusion criteria were any psychiatric comorbidities or previous treatment of acrophobia within the last 6 months, metal parts in the head, medical implants, increased intracranial pressure, pregnancy, current involvement in psycho- or pharmacotherapy, cardiovascular or neurological diseases, a history of tinnitus, or family history of epilepsy (for details see [@CIT0010]). Additionally, 28 healthy female controls drawn from a larger, well-characterized pool of healthy probands (see [@CIT0005]) were matched to the sample of patients with acrophobia by age (39.61±6.68 years, *t* = -1.8, n.s.). This study was approved by the ethics committees of the Universities of Würzburg and Münster, Germany and was conducted according to the ethical principles of the Helsinki Declaration. Written informed consent was obtained from all participants.

Treatment {#s4}
---------

After receiving psycho-educative information in written form, patients performed 2 exposure sessions within 2 weeks in a 3- x 4-m, 5-sided Cave Automatic Virtual Environment operated by the Department of Psychology, University of Würzburg (PsyCave; see [@CIT0014]). Prior to the exposure session, 20 minutes of excitatory rTMS was applied over the medial prefrontal cortex in a lying position (10 Hz, verum or sham; CBT\[-rTMS\] and CBT\[+rTMS\]; see [@CIT0010]).

Psychometric assessment of fear of heights was evaluated before (T0) and after (T1) the therapeutic intervention using the Acrophobia Questionnaire (AQ, Anxiety Subscale; [@CIT0004]) and the Attitude Towards Heights Questionnaire (ATHQ; [@CIT0001]). Patients were instructed not to change any lifestyle patterns including smoking behavior from T0 to T1.

MAOA Methylation Analysis {#s5}
-------------------------

In the patient sample, DNA was isolated from EDTA blood taken at T0 and T1 using the FlexiGene DNA Kit (Qiagen). After sodium bisulfite conversion (EpiTect 96 Bisulfite Kit, Qiagen), an amplicon comprising *MAOA* exon I as well as the adjacent promoter and intron I regions (chromosome X, GRCh38.p2 Primary Assembly, NCBI Reference Sequence: NC_000023.11, 43656260--43656613) was PCR-amplified following a published protocol ([@CIT0005], [@CIT0008]; [@CIT0025], [@CIT0026]) and sequenced (ABI 3730XL, LGC Genomics). The obtained sequences were quantitatively analyzed using the Epigenetic Sequencing Methylation software (ESME; [@CIT0013]; cf. [@CIT0005], [@CIT0006], [@CIT0007], [@CIT0008]; [@CIT0022]; [@CIT0008], [@CIT0025], [@CIT0026]). Electropherograms were robustly readable for 13 CpG sites (CpG1 = 43656 316; CpG2 = 43656327; CpG3 = 43656 362; CpG4 = 43656368; CpG5 = 43656370; CpG6 = 43656383; CpG7 = 43656386; CpG8 = 43656392; CpG9 = 43656398; CpG10 = 43656427; CpG11 = 43656432; CpG12 = 43656514; CpG13 = 43656553). Healthy controls had been assessed for *MAOA* methylation using the same methods as applied to the present patient sample (see [@CIT0005]). Quality control was performed as described previously (cf. [@CIT0005]; [@CIT0025]). No participant had to be excluded from the reported analyses when applying quality control (data missing for CpG1 in 3 patients).

Additionally, all patients and controls were genotyped for the *MAOA* VNTR according to published protocols ([@CIT0015]) and stratified into low (33/34/3a4/35) and high expression (44/45) genotype groups (cf. [@CIT0015]; [@CIT0008]).

Functional Analysis {#s6}
-------------------

Functional analysis was accomplished using the pCpGfree-promoter-*Lucia* vector (InvivoGen) expressing a *Lucia* luciferase under a human elongation factor-1 (hEF1) promoter. The insert comprising CpGs 1--13 was PCR-amplified and ligated into the linearized vector using T4 DNA Ligase (Invitrogen). The vectors were methylated using the CpG methyltransferase M.SssI (NEB) and transfected to HEK293 cells (ECACC) using the TransFast reagent (Promega). Luciferase assays were performed using the Stop & Glo® Reagent (Promega) on a GloMax+ Luminometer (Promega), and *Lucia* luciferase activity was normalized using a co-transfected pGL4.74 *Renilla* luciferase control vector. All analyses were conducted in technical triplicates.

Statistical Analysis {#s7}
--------------------

Differences in *MAOA* methylation levels between patients and controls as well as between genotype groups were tested by means of independent samples *t* tests. The association between baseline methylation and treatment response as defined as the intra-individual relative change (in percent) in clinical symptom scores (AQ Anxiety) was assessed by means of linear regression analysis and controlled for genotype and TMS status. Changes in *MAOA* methylation levels following therapy were tested using repeated-measures ANOVA and controlled for grouped genotype and TMS randomization. Symptom changes were evaluated by means of paired sample *t* tests. A partial correlation was run to determine the relationship between individual changes in methylation (T1-T0) and symptom improvement (T1-T0) whilst controlling for baseline methylation (T0), genotype, and TMS status. Luciferase assay data were normalized to transfection efficiency by *Renilla* luciferase control and z-transformed to eliminate day and measurement specific fluctuations. All tests were carried out 2-sided, and an alpha level of \<0.05 was considered significant. Given the present proof-of-concept approach and high correlation between the 13 individual CpG sites (data not shown), no correction for multiple testing was applied when analyzing single CpG sites.

Results {#s8}
=======

Mean scores on both questionnaires decreased significantly after the therapeutic intervention (AQ Anxiety T0: 57.05±18.11, T1: 43.47±18.91, *t* = 4.61, *P* \< .001; ATHQ Total T0: 37.86±16.56, T1: 26.89±9.53, *t* = 4.59, *P* \< .001; ATHQ Danger T0: 18.32±8.19, T1: 12.61±5.34, *t* = 5.19, *P* \< .001). For this female patient subsample, no difference was discerned between the CBT(-rTMS) and CBT(+rTMS) groups regarding treatment response (data not shown), allowing for a joint epigenetic analysis of the 2 groups in the present context.

At T0, average *MAOA* methylation (0.432±0.021) did not correlate with age or disease severity according to AQ Anxiety or ATHQ Total/Danger scores (all *P* \> .05). No influence of grouped genotype (low expression \[33/34/3a4/35\]: n = 17 patients and n = 19 controls; high expression \[44/45\]: n = 11 patients and n = 9 controls) was discerned on average *MAOA* methylation or questionnaire scores at T0 (all *P* \> .05). Furthermore, patients and controls did not differ in genotype distribution (*Χ*^*2*^ = .311, *P* = .577).

Average *MAOA* methylation as well as methylation at CpGs 1--8 and 10--13 differed significantly between patients with acrophobia at baseline (T0) and healthy controls. Patients were characterized by significantly lower average methylation levels, specifically driven by single CpGs 1--8, 10, and 11 (for details see [Table 1](#T1){ref-type="table"}).

###### 

*MAOA* Methylation Levels in Patients with Acrophobia and Healthy Controls

                        Patients (n = 28) Mean (SE)   Controls (n = 28) Mean (SE)   Statistics   
  --------------------- ----------------------------- ----------------------------- ------------ --------
  Average methylation   0.432 (0.004)                 0.4712 (0.008)                4.488        \<.001
  CpG1                  0.359 (0.009)                 0.4594 (0.011)                7.040        \<.001
  CpG2                  0.358 (0.010)                 0.3927 (0.011)                2.366        .022
  CpG3                  0.370 (0.008)                 0.4097 (0.011)                2.873        .006
  CpG4                  0.403 (0.008)                 0.5895 (0.020)                8.756        \<.001
  CpG5                  0.286 (0.009)                 0.3375 (0.016)                2.800        .008
  CpG6                  0.361 (0.009)                 0.4246 (0.011)                4.403        \<.001
  CpG7                  0.441 (0.007)                 0.4964 (0.009)                4.900        \<.001
  CpG8                  0.318 (0.009)                 0.3751 (0.010)                4.284        \<.001
  CpG9                  0.467 (0.006)                 0.4836 (0.009)                1.575        .121
  CpG10                 0.482 (0.005)                 0.5049 (0.007)                2.758        .008
  CpG11                 0.282 (0.009)                 0.3138 (0.008)                2.571        .013
  CpG12                 0.913 (0.007)                 0.8484 (0.020)                -3.082       .003
  CpG13                 0.569 (0.011)                 0.4896 (0.018)                -3.670       .001

*P*-values from independent samples *t* test.

A positive change in AQ Anxiety scores indicating treatment response was seen in 20 patients (71.4%). While no significant association between baseline average *MAOA* methylation and treatment response could be discerned, differences were observed regarding CpG1 (*β* = .567, *P* = .003) and, approaching trend levels of significance, CpG5 (*β* = .340, *P* = .086) and CpG6 (*β* = .331, *P* = .091), with lower baseline methylation predicting impaired treatment response.

Following therapy, *MAOA* methylation increased significantly in the patient group for average methylation (T1: 0.441±0.029, *F* = 4.703, *P* = .040) and specifically at CpG4 (T1: 0.420±0.040, *F* = 4.708, *P* = .040), CpG6 (T1: 0.375±0.051, *F* = 4.954, *P* = .036), CpG8 (T1: 0.334±0.053, *F* = 10.204, *P* = .004) and CpG9 (T1: 0.484±0.035, *F* = 10.249, *P* = .004) ([Figure 1A](#F1){ref-type="fig"}). Methylation at all other CpG sites did not change significantly from T0 to T1 (all *P* \> .05).

![*MAOA* methylation and treatment response in acrophobia. (A) Significant changes in *MAOA* methylation from baseline (T0; black bars) to post therapy (T1; grey bars) in n = 28 female patients with acrophobia at single CpG sites 4, 6, 8, and 9 and for average methylation (CpGs 1--13); mean ± SE. \**P* \< .05, \*\**P* \< .01. (B) Correlation between reduction in anxiety severity (Acrophobia Questionnaire \[AQ\] Anxiety score from T0 to T1) and *MAOA* average methylation change from T0 to T1 (*r* = -0.449, *P* = .019).](pyy05001){#F1}

In the main analyses regarding methylation change dependent on treatment response as measured by changes in AQ Anxiety or ATHQ Total/Danger scores, respectively, negative correlations indicated clinical symptom improvement to go along with an increase in average *MAOA* methylation (AQ Anxiety: *r* = -0.465, *P* = .019, [Figure 1B](#F1){ref-type="fig"}; ATHQ Danger: *r* = -0.496, *P* = .012). This pattern held true for several individual CpG sites (AQ Anxiety: CpG2: *r* = -0.455, *P* = .022; CpG3: *r* = -0.398, *P* = .049; CpG7: *r* = -0.459, *P* = .021; CpG9: *r* = -0.399, *P* = .048; CpG10: *r* = -0.527, *P* = .007; ATHQ Total: CpG9: *r* = -0.402, *P* = .047; ATHQ Danger: CpG2: *r* = -.412, *P* = .041; CpG3: *r* = -0.401, *P* = .047; CpG7: *r* = -0.473, *P* = .017; CpG9: *r* = -0.541, *P* = .005; CpG11: *r* = -0.424, *P* = .035).

Applying *in vitro* luciferase assays, nonmethylated pCpGfree-promoter *Lucia*\_*MAOA* vectors showed a significant increase in normalized *Lucia* luciferase activity compared with pCpGfree-promoter *Lucia*\_*MAOA* vectors methylated with M.SssI prior to transfection (*t* = 4.157, *p* \< .001; [Figure 2](#F2){ref-type="fig"}). PCpGfree-promoter *Lucia* vectors without insert showed no significant difference between the methylated and the nonmethylated state (*t* = 0.394, *p* = .70; [Figure 2](#F2){ref-type="fig"}).

![Functional analysis of *MAOA* promoter/exon I/intron I DNA methylation using luciferase-based reporter gene assays. Left: Normalized reporter gene activity was significantly decreased in the presence of pCpGfree-promoter *Lucia_MAOA* vectors containing the methylated insert spanning CpGs 1--13 compared with those carrying a nonmethylated insert; \*\*\**P* \< .001. Right: No significant difference in normalized reporter gene activity was discerned between methylated or non-methylated pCpGfree-promoter *Lucia* control vectors lacking the insert of the sequence spanning CpGs 1--13.](pyy05002){#F2}

Discussion {#s9}
==========

The present finding of (I) decreased *MAOA* methylation in patients with acrophobia compared with healthy controls, (II) decreased methylation at a single *MAOA* CpG site to predict treatment response, and (III) increasing *MAOA* methylation along with treatment response further strengthens and extends the emerging body of evidence for a potential role of *MAOA* methylation in the pathogenesis of fear-related disorders. Additionally, in line with the hypothesis of epigenetically driven neuroplasticity underlying response to extinction-related psychotherapeutic interventions ([@CIT0021]), *MAOA* methylation might be worthwhile to be further investigated as a possible correlate of successful extinction treatment (cf. in panic disorder: [@CIT0025]). Furthermore, using luciferase-based reporter gene assays, we demonstrated increased methylation of the therapy-modulated region to drive decreased gene expression, which is line with a previous functional *in vitro* assay ([@CIT0003]) and blood *MAOA* methylation correlating inversely with brain MAO-A levels *in vivo* using \[(11)C\]clorgyline positron emission tomography ([@CIT0020]). These functional results also support the notion that not only methylation of the promoter but also of exon I with its adjacent promoter and intron I regions seems to be linked to transcriptional repression ([@CIT0002]). In sum, we hypothesize that in acrophobia, decreased availability of monoamines conferred by decreased *MAOA* methylation might be reversible by remethylation during the course of a successful therapeutic intervention.

The present study thereby adds to the only recently burgeoning evidence for epigenetic mechanisms possibly constituting dynamic biological correlates of therapeutic interventions in mental disorders (for review, see [@CIT0019]). In anxiety disorders, besides the above-mentioned study ([@CIT0025]) only 2 other studies have investigated methylation dynamics with respect to treatment effects. Here, methylation changes in the serotonin transporter (*5-HTT*) gene as well as in the FK506-binding protein 5 (*FKBP5*) gene were found to be associated with response to psychotherapy in children with mixed primary anxiety disorder diagnoses and obsessive-compulsive disorder ([@CIT0016], [@CIT0017]).

A major limitation of the present study entailing the risk of false positive results is the relatively small sample size owed to the proof-of-concept design, strict inclusion/exclusion criteria, and inclusion of female patients only due to the X-chromosomal location of the *MAOA* gene and previous observations of female-specific effects of genetic as well as epigenetic *MAOA* variation in anxiety disorders ([@CIT0005]; [@CIT0015]; [@CIT0025]). Thus, despite comparability to previous treatment-epigenetic studies regarding size (e.g., [@CIT0025]), replication in larger samples as well as in mixed samples including also male patients is warranted. Given that no control group was available paralleling the time course of treatment in the patient sample, the observed changes in *MAOA* methylation in patients cannot conclusively be attributed to the effects of the intervention but could rather be an inconsequential side effect arising from a significant environmental stimulus. Also, despite no statistically significant influence having been detected, psychotherapeutic and rTMS effects on DNA methylation changes along with clinical symptom improvement cannot be differentiated. In general, DNA methylation was measured in peripheral blood samples entailing cell composition effects driven by a vast amount of factors such as inflammation, diet, exercise, stress, or hormonal status as a possible confounder. Also, while patients were instructed not to change smoking patterns from T0 to T1, smoking patterns could still have confounded the present results. Furthermore, data from *in vitro* luciferase assays spanning 13 CpG sites do not allow for evaluating *MAOA* gene regulation *in toto* or at single CpG sites and thus are to be considered suggestive, but not conclusive, particularly since different CpG sites were found to predict or correlate with treatment response, respectively. Data on *MAOA* mRNA expression in apt tissue dependent on individual *MAOA* methylation status would aid in further defining the *in vivo* physiological consequences of *MAOA* promoter hypomethylation (cf. [@CIT0011]). Along these lines, despite some evidence for their potential as viable markers of central processes (e.g., [@CIT0020]), peripheral methylation patterns do not necessarily allow for deductions regarding *MAOA* methylation status in brain tissue. Finally, localized changes such as the presently identified *MAOA* methylation patterns might reflect global changes in genomic DNA methylation either by CpG hyper- and hypomethylation necessitating investigation by means of epigenome-wide association studies in larger, sufficiently powered samples.

In sum, while warranting replication and considering all caveats mentioned above, the present psychotherapy-epigenetic study for the first time suggests functionally relevant *MAOA* methylation changes as a potential epigenetic correlate of response to cognitive behavioral psychotherapy in acrophobia and corroborates a previous independent finding in panic disorder ([@CIT0025]). The emerging notion of epigenetic signatures as a core mechanism of action of fear extinction might aid in probing pharmacological treatment enhancers such as MAO-inhibitors or, in a more general sense, drugs inducing epigenetic changes as augmentation strategies for lasting extinction effects and is thereby hoped to contribute to a more effective treatment based on individual epigenetic information.
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